Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?

Loading...
Thumbnail Image

Date

2019-04

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

5
views
8
downloads

Citation Stats

Attention Stats

Abstract

Invasive mould infections are an increasing cause of morbidity and mortality globally, mainly due to increasing numbers of immunocompromised individuals at risk for fungal infections. The introduction of broad spectrum triazoles, which are much better tolerated compared to conventional amphotericin B formulations, has increased survival, particularly in invasive mould infection. However, early initiation of appropriate antifungal treatment remains a major predictor of outcome in invasive mould infection, but despite significant advances in diagnosis of these diseases, early diagnosis remains a challenge. As a result, prophylaxis with mould-active triazoles is widely used for those patients at highest risk for invasive mould infection, including patients with prolonged neutropenia after induction chemotherapy for acute myeloid leukemia and patients with graft-versus-host-disease. Posaconazole is the recommended drug of choice for antimould prophylaxis in these high-risk patients. Voriconazole has its primary role in treatment of invasive aspergillosis but not in prophylaxis. Recently, isavuconazole has been introduced as an excellent alternative to voriconazole for primary treatment of invasive aspergillosis in patients with hematological malignancies. Compared to voriconazole, isavuconazole and posaconazole have broader activity against moulds and are therefore also an option for treatment of mucormycosis in the presence of intolerance or contraindications against liposomal amphotericin B.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1093/mmy/myy052

Publication Info

Jenks, Jeffrey D, Sanjay R Mehta and Martin Hoenigl (2019). Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?. Medical mycology, 57(Supplement_2). pp. S168–S178. 10.1093/mmy/myy052 Retrieved from https://hdl.handle.net/10161/28623.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Jenks

Jeffrey Daniel Jenks

Adjunct Associate Professor in the Department of Medicine

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.